Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy

Stanford Health Care

Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer.

Adipose tissue and skeletal muscle wasting precede clinical diagnosis of pancreatic cancer. Nature communications Babic, A., Rosenthal, M. H., Sundaresan, T. K., Khalaf, N., Lee, V., Brais, L. K., Loftus, M., Caplan, L., Denning, S., Gurung, A., Harrod, J., Schawkat, K., Yuan, C., Wang, Q. L., Lee, A. A., Biller, L. H., Yurgelun, M. B., Ng, K., Nowak, J. A., Aguirre, A. J., Bhatia, S. N., Vander Heiden, M. G., Van Den Eeden, S. K., Caan, B. J., Wolpin, B. M. 2023; 14 (1): 4317

Abstract

Patients with pancreatic cancer commonly develop weight loss and muscle wasting. Whether adipose tissue and skeletal muscle losses begin before diagnosis and the potential utility of such losses for earlier cancer detection are not well understood. We quantify skeletal muscle and adipose tissue areas from computed tomography (CT) imaging obtained 2 months to 5 years before cancer diagnosis in 714 pancreatic cancer cases and 1748 matched controls. Adipose tissue loss is identified up to 6 months, and skeletal muscle wasting is identified up to 18 months before the clinical diagnosis of pancreatic cancer and is not present in the matched control population. Tissue losses are of similar magnitude in cases diagnosed with localized compared with metastatic disease and are not correlated with at-diagnosis circulating levels of CA19-9. Skeletal muscle wasting occurs in the 1-2 years before pancreatic cancer diagnosis and may signal an upcoming diagnosis of pancreatic cancer.

View details for DOI 10.1038/s41467-023-40024-3

View details for PubMedID 37463915

View details for PubMedCentralID PMC10354105